Global Immunotherapy Drugs Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	163 Pages	TechNavio	November, 2023	INF18352118

Best Price Guarantee
Price	from $2,500
Length	163 Pages
Publisher	TechNavio
Published Date	November, 2023
SKU	INF18352118

Global Immunotherapy Drugs Market 2024-2028

The immunotherapy drugs market is forecasted to grow by USD 111.35 bn during 2023-2028, accelerating at a CAGR of 11.31% during the forecast period. The report on the immunotherapy drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of cancer, growing investments in pharmaceutical technology, and increasing awareness in patients.

Technavio's immunotherapy drugs market is segmented as below:

By End-user

Hospitals
Clinics
Others

By Type

Monoclonal antibodies
Vaccines
Immune checkpoint inhibitors
Others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the emerging drug development techniques as one of the prime reasons driving the immunotherapy drugs market growth during the next few years. Also, growing focus on personalized medicine products and expanding application beyond oncology will lead to sizable demand in the market.

The report on the immunotherapy drugs market covers the following areas:

Immunotherapy drugs market sizing
Immunotherapy drugs market forecast
Immunotherapy drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading immunotherapy drugs market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celldex Therapeutics Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Immatics NV, Incyte Corp., Johnson and Johnson, Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., ElevateBio, and Genmab AS. Also, the immunotherapy drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Global Market Characteristics; Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape; Exhibit 05: Executive Summary - Chart on Market Segmentation by End-user; Exhibit 06: Executive Summary - Chart on Market Segmentation by Type; Exhibit 07: Executive Summary - Chart on Incremental Growth; Exhibit 08: Executive Summary - Data Table on Incremental Growth; Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 10: Parent market; Exhibit 11: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 12: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 13: Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion); Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion); Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global immunotherapy drugs market 2018 - 2022; Exhibit 18: Historic Market Size - Data Table on global immunotherapy drugs market 2018 - 2022 ($ billion); 4.2 End-user Segment Analysis 2018 - 2022; Exhibit 19: Historic Market Size - End-user Segment 2018 - 2022 ($ billion); 4.3 Type Segment Analysis 2018 - 2022; Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ billion); 4.4 Geography Segment Analysis 2018 - 2022; Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion); 4.5 Country Segment Analysis 2018 - 2022; Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 23: Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by End-user: 6.1 Market segments; Exhibit 30: Chart on End-user - Market share 2023-2028 (%); Exhibit 31: Data Table on End-user - Market share 2023-2028 (%); 6.2 Comparison by End-user; Exhibit 32: Chart on Comparison by End-user; Exhibit 33: Data Table on Comparison by End-user; 6.3 Hospitals - Market size and forecast 2023-2028; Exhibit 34: Chart on Hospitals - Market size and forecast 2023-2028 ($ billion); Exhibit 35: Data Table on Hospitals - Market size and forecast 2023-2028 ($ billion); Exhibit 36: Chart on Hospitals - Year-over-year growth 2023-2028 (%); Exhibit 37: Data Table on Hospitals - Year-over-year growth 2023-2028 (%); 6.4 Clinics - Market size and forecast 2023-2028; Exhibit 38: Chart on Clinics - Market size and forecast 2023-2028 ($ billion); Exhibit 39: Data Table on Clinics - Market size and forecast 2023-2028 ($ billion); Exhibit 40: Chart on Clinics - Year-over-year growth 2023-2028 (%); Exhibit 41: Data Table on Clinics - Year-over-year growth 2023-2028 (%); 6.5 Others - Market size and forecast 2023-2028; Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ billion); Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ billion); Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%); 6.6 Market opportunity by End-user; Exhibit 46: Market opportunity by End-user ($ billion); Exhibit 47: Data Table on Market opportunity by End-user ($ billion)
7 Market Segmentation by Type: 7.1 Market segments; Exhibit 48: Chart on Type - Market share 2023-2028 (%); Exhibit 49: Data Table on Type - Market share 2023-2028 (%); 7.2 Comparison by Type; Exhibit 50: Chart on Comparison by Type; Exhibit 51: Data Table on Comparison by Type; 7.3 Monoclonal antibodies - Market size and forecast 2023-2028; Exhibit 52: Chart on Monoclonal antibodies - Market size and forecast 2023-2028 ($ billion); Exhibit 53: Data Table on Monoclonal antibodies - Market size and forecast 2023-2028 ($ billion); Exhibit 54: Chart on Monoclonal antibodies - Year-over-year growth 2023-2028 (%); Exhibit 55: Data Table on Monoclonal antibodies - Year-over-year growth 2023-2028 (%); 7.4 Vaccines - Market size and forecast 2023-2028; Exhibit 56: Chart on Vaccines - Market size and forecast 2023-2028 ($ billion); Exhibit 57: Data Table on Vaccines - Market size and forecast 2023-2028 ($ billion); Exhibit 58: Chart on Vaccines - Year-over-year growth 2023-2028 (%); Exhibit 59: Data Table on Vaccines - Year-over-year growth 2023-2028 (%); 7.5 Immune checkpoint inhibitors - Market size and forecast 2023-2028; Exhibit 60: Chart on Immune checkpoint inhibitors - Market size and forecast 2023-2028 ($ billion); Exhibit 61: Data Table on Immune checkpoint inhibitors - Market size and forecast 2023-2028 ($ billion); Exhibit 62: Chart on Immune checkpoint inhibitors - Year-over-year growth 2023-2028 (%); Exhibit 63: Data Table on Immune checkpoint inhibitors - Year-over-year growth 2023-2028 (%); 7.6 Others - Market size and forecast 2023-2028; Exhibit 64: Chart on Others - Market size and forecast 2023-2028 ($ billion); Exhibit 65: Data Table on Others - Market size and forecast 2023-2028 ($ billion); Exhibit 66: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibit 67: Data Table on Others - Year-over-year growth 2023-2028 (%); 7.7 Market opportunity by Type; Exhibit 68: Market opportunity by Type ($ billion); Exhibit 69: Data Table on Market opportunity by Type ($ billion)
8 Customer Landscape: 8.1 Customer landscape overview; Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%); 9.2 Geographic comparison; Exhibit 73: Chart on Geographic comparison; Exhibit 74: Data Table on Geographic comparison; 9.3 North America - Market size and forecast 2023-2028; Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion); Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion); Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%); 9.4 Europe - Market size and forecast 2023-2028; Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion); Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion); Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%); 9.5 Asia - Market size and forecast 2023-2028; Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion); Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion); Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%); 9.6 Rest of World (ROW) - Market size and forecast 2023-2028; Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 9.7 US - Market size and forecast 2023-2028; Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion); Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion); Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%); Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%); 9.8 China - Market size and forecast 2023-2028; Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ billion); Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ billion); Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%); Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%); 9.9 Germany - Market size and forecast 2023-2028; Exhibit 99: Chart on Germany - Market size and forecast 2023-2028 ($ billion); Exhibit 100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion); Exhibit 101: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibit 102: Data Table on Germany - Year-over-year growth 2023-2028 (%); 9.10 UK - Market size and forecast 2023-2028; Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ billion); Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ billion); Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%); 9.11 Japan - Market size and forecast 2023-2028; Exhibit 107: Chart on Japan - Market size and forecast 2023-2028 ($ billion); Exhibit 108: Data Table on Japan - Market size and forecast 2023-2028 ($ billion); Exhibit 109: Chart on Japan - Year-over-year growth 2023-2028 (%); Exhibit 110: Data Table on Japan - Year-over-year growth 2023-2028 (%); 9.12 Market opportunity By Geographical Landscape; Exhibit 111: Market opportunity By Geographical Landscape ($ billion); Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)
10 Drivers, Challenges, and Trends: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 113: Impact of drivers and challenges in 2023 and 2028; 10.4 Market trends
11 Vendor Landscape: 11.1 Overview; 11.2 Vendor landscape; Exhibit 114: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 115: Overview on factors of disruption; 11.4 Industry risks; Exhibit 116: Impact of key risks on business
12 Vendor Analysis: 12.1 Vendors covered; Exhibit 117: Vendors covered; 12.2 Market positioning of vendors; Exhibit 118: Matrix on vendor position and classification; 12.3 AbbVie Inc.; Exhibit 119: AbbVie Inc. - Overview; Exhibit 120: AbbVie Inc. - Product / Service; Exhibit 121: AbbVie Inc. - Key news; Exhibit 122: AbbVie Inc. - Key offerings; 12.4 Amgen Inc.; Exhibit 123: Amgen Inc. - Overview; Exhibit 124: Amgen Inc. - Product / Service; Exhibit 125: Amgen Inc. - Key offerings; 12.5 AstraZeneca Plc; Exhibit 126: AstraZeneca Plc - Overview; Exhibit 127: AstraZeneca Plc - Product / Service; Exhibit 128: AstraZeneca Plc - Key news; Exhibit 129: AstraZeneca Plc - Key offerings; 12.6 Bayer AG; Exhibit 130: Bayer AG - Overview; Exhibit 131: Bayer AG - Business segments; Exhibit 132: Bayer AG - Key news; Exhibit 133: Bayer AG - Key offerings; Exhibit 134: Bayer AG - Segment focus; 12.7 BioNTech SE; Exhibit 135: BioNTech SE - Overview; Exhibit 136: BioNTech SE - Product / Service; Exhibit 137: BioNTech SE - Key offerings; 12.8 Boehringer Ingelheim International GmbH; Exhibit 138: Boehringer Ingelheim International GmbH - Overview; Exhibit 139: Boehringer Ingelheim International GmbH - Business segments; Exhibit 140: Boehringer Ingelheim International GmbH - Key news; Exhibit 141: Boehringer Ingelheim International GmbH - Key offerings; Exhibit 142: Boehringer Ingelheim International GmbH - Segment focus; 12.9 Bristol Myers Squibb Co.; Exhibit 143: Bristol Myers Squibb Co. - Overview; Exhibit 144: Bristol Myers Squibb Co. - Product / Service; Exhibit 145: Bristol Myers Squibb Co. - Key news; Exhibit 146: Bristol Myers Squibb Co. - Key offerings; 12.10 F. Hoffmann La Roche Ltd.; Exhibit 147: F. Hoffmann La Roche Ltd. - Overview; Exhibit 148: F. Hoffmann La Roche Ltd. - Business segments; Exhibit 149: F. Hoffmann La Roche Ltd. - Key news; Exhibit 150: F. Hoffmann La Roche Ltd. - Key offerings; Exhibit 151: F. Hoffmann La Roche Ltd. - Segment focus; 12.11 Gilead Sciences Inc.; Exhibit 152: Gilead Sciences Inc. - Overview; Exhibit 153: Gilead Sciences Inc. - Product / Service; Exhibit 154: Gilead Sciences Inc. - Key news; Exhibit 155: Gilead Sciences Inc. - Key offerings; 12.12 GlaxoSmithKline Plc; Exhibit 156: GlaxoSmithKline Plc - Overview; Exhibit 157: GlaxoSmithKline Plc - Business segments; Exhibit 158: GlaxoSmithKline Plc - Key news; Exhibit 159: GlaxoSmithKline Plc - Key offerings; Exhibit 160: GlaxoSmithKline Plc - Segment focus; 12.13 Immatics NV; Exhibit 161: Immatics NV - Overview; Exhibit 162: Immatics NV - Product / Service; Exhibit 163: Immatics NV - Key offerings; 12.14 Johnson and Johnson; Exhibit 164: Johnson and Johnson - Overview; Exhibit 165: Johnson and Johnson - Business segments; Exhibit 166: Johnson and Johnson - Key news; Exhibit 167: Johnson and Johnson - Key offerings; Exhibit 168: Johnson and Johnson - Segment focus; 12.15 Novartis AG; Exhibit 169: Novartis AG - Overview; Exhibit 170: Novartis AG - Business segments; Exhibit 171: Novartis AG - Key offerings; Exhibit 172: Novartis AG - Segment focus; 12.16 Pfizer Inc.; Exhibit 173: Pfizer Inc. - Overview; Exhibit 174: Pfizer Inc. - Product / Service; Exhibit 175: Pfizer Inc. - Key news; Exhibit 176: Pfizer Inc. - Key offerings; 12.17 Sanofi SA; Exhibit 177: Sanofi SA - Overview; Exhibit 178: Sanofi SA - Business segments; Exhibit 179: Sanofi SA - Key news; Exhibit 180: Sanofi SA - Key offerings; Exhibit 181: Sanofi SA - Segment focus
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 182: Inclusions checklist; Exhibit 183: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 184: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 185: Research methodology; Exhibit 186: Validation techniques employed for market sizing; Exhibit 187: Information sources; 13.5 List of abbreviations; Exhibit 188: List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by End-user; Exhibits6: Executive Summary - Chart on Market Segmentation by Type; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Vendor Market Positioning; Exhibits10: Parent market; Exhibits11: Market Characteristics; Exhibits12: Offerings of vendors included in the market definition; Exhibits13: Market segments; Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion); Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion); Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits18: Historic Market Size - Data Table on global immunotherapy drugs market 2018 - 2022 ($ billion); Exhibits19: Historic Market Size - End-user Segment 2018 - 2022 ($ billion); Exhibits20: Historic Market Size - Type Segment 2018 - 2022 ($ billion); Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion); Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion); Exhibits23: Five forces analysis - Comparison between 2023 and 2028; Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits29: Chart on Market condition - Five forces 2023 and 2028; Exhibits30: Chart on End-user - Market share 2023-2028 (%); Exhibits31: Data Table on End-user - Market share 2023-2028 (%); Exhibits32: Chart on Comparison by End-user; Exhibits33: Data Table on Comparison by End-user; Exhibits34: Chart on Hospitals - Market size and forecast 2023-2028 ($ billion); Exhibits35: Data Table on Hospitals - Market size and forecast 2023-2028 ($ billion); Exhibits36: Chart on Hospitals - Year-over-year growth 2023-2028 (%); Exhibits37: Data Table on Hospitals - Year-over-year growth 2023-2028 (%); Exhibits38: Chart on Clinics - Market size and forecast 2023-2028 ($ billion); Exhibits39: Data Table on Clinics - Market size and forecast 2023-2028 ($ billion); Exhibits40: Chart on Clinics - Year-over-year growth 2023-2028 (%); Exhibits41: Data Table on Clinics - Year-over-year growth 2023-2028 (%); Exhibits42: Chart on Others - Market size and forecast 2023-2028 ($ billion); Exhibits43: Data Table on Others - Market size and forecast 2023-2028 ($ billion); Exhibits44: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibits45: Data Table on Others - Year-over-year growth 2023-2028 (%); Exhibits46: Market opportunity by End-user ($ billion); Exhibits47: Data Table on Market opportunity by End-user ($ billion); Exhibits48: Chart on Type - Market share 2023-2028 (%); Exhibits49: Data Table on Type - Market share 2023-2028 (%); Exhibits50: Chart on Comparison by Type; Exhibits51: Data Table on Comparison by Type; Exhibits52: Chart on Monoclonal antibodies - Market size and forecast 2023-2028 ($ billion); Exhibits53: Data Table on Monoclonal antibodies - Market size and forecast 2023-2028 ($ billion); Exhibits54: Chart on Monoclonal antibodies - Year-over-year growth 2023-2028 (%); Exhibits55: Data Table on Monoclonal antibodies - Year-over-year growth 2023-2028 (%); Exhibits56: Chart on Vaccines - Market size and forecast 2023-2028 ($ billion); Exhibits57: Data Table on Vaccines - Market size and forecast 2023-2028 ($ billion); Exhibits58: Chart on Vaccines - Year-over-year growth 2023-2028 (%); Exhibits59: Data Table on Vaccines - Year-over-year growth 2023-2028 (%); Exhibits60: Chart on Immune checkpoint inhibitors - Market size and forecast 2023-2028 ($ billion); Exhibits61: Data Table on Immune checkpoint inhibitors - Market size and forecast 2023-2028 ($ billion); Exhibits62: Chart on Immune checkpoint inhibitors - Year-over-year growth 2023-2028 (%); Exhibits63: Data Table on Immune checkpoint inhibitors - Year-over-year growth 2023-2028 (%); Exhibits64: Chart on Others - Market size and forecast 2023-2028 ($ billion); Exhibits65: Data Table on Others - Market size and forecast 2023-2028 ($ billion); Exhibits66: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibits67: Data Table on Others - Year-over-year growth 2023-2028 (%); Exhibits68: Market opportunity by Type ($ billion); Exhibits69: Data Table on Market opportunity by Type ($ billion); Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits71: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibits72: Data Table on Market share By Geographical Landscape 2023-2028 (%); Exhibits73: Chart on Geographic comparison; Exhibits74: Data Table on Geographic comparison; Exhibits75: Chart on North America - Market size and forecast 2023-2028 ($ billion); Exhibits76: Data Table on North America - Market size and forecast 2023-2028 ($ billion); Exhibits77: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits78: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits79: Chart on Europe - Market size and forecast 2023-2028 ($ billion); Exhibits80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion); Exhibits81: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits82: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits83: Chart on Asia - Market size and forecast 2023-2028 ($ billion); Exhibits84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion); Exhibits85: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits86: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibits88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibits89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits91: Chart on US - Market size and forecast 2023-2028 ($ billion); Exhibits92: Data Table on US - Market size and forecast 2023-2028 ($ billion); Exhibits93: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits94: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits95: Chart on China - Market size and forecast 2023-2028 ($ billion); Exhibits96: Data Table on China - Market size and forecast 2023-2028 ($ billion); Exhibits97: Chart on China - Year-over-year growth 2023-2028 (%); Exhibits98: Data Table on China - Year-over-year growth 2023-2028 (%); Exhibits99: Chart on Germany - Market size and forecast 2023-2028 ($ billion); Exhibits100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion); Exhibits101: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits102: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits103: Chart on UK - Market size and forecast 2023-2028 ($ billion); Exhibits104: Data Table on UK - Market size and forecast 2023-2028 ($ billion); Exhibits105: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibits106: Data Table on UK - Year-over-year growth 2023-2028 (%); Exhibits107: Chart on Japan - Market size and forecast 2023-2028 ($ billion); Exhibits108: Data Table on Japan - Market size and forecast 2023-2028 ($ billion); Exhibits109: Chart on Japan - Year-over-year growth 2023-2028 (%); Exhibits110: Data Table on Japan - Year-over-year growth 2023-2028 (%); Exhibits111: Market opportunity By Geographical Landscape ($ billion); Exhibits112: Data Tables on Market opportunity By Geographical Landscape ($ billion); Exhibits113: Impact of drivers and challenges in 2023 and 2028; Exhibits114: Overview on Criticality of inputs and Factors of differentiation; Exhibits115: Overview on factors of disruption; Exhibits116: Impact of key risks on business; Exhibits117: Vendors covered; Exhibits118: Matrix on vendor position and classification; Exhibits119: AbbVie Inc. - Overview; Exhibits120: AbbVie Inc. - Product / Service; Exhibits121: AbbVie Inc. - Key news; Exhibits122: AbbVie Inc. - Key offerings; Exhibits123: Amgen Inc. - Overview; Exhibits124: Amgen Inc. - Product / Service; Exhibits125: Amgen Inc. - Key offerings; Exhibits126: AstraZeneca Plc - Overview; Exhibits127: AstraZeneca Plc - Product / Service; Exhibits128: AstraZeneca Plc - Key news; Exhibits129: AstraZeneca Plc - Key offerings; Exhibits130: Bayer AG - Overview; Exhibits131: Bayer AG - Business segments; Exhibits132: Bayer AG - Key news; Exhibits133: Bayer AG - Key offerings; Exhibits134: Bayer AG - Segment focus; Exhibits135: BioNTech SE - Overview; Exhibits136: BioNTech SE - Product / Service; Exhibits137: BioNTech SE - Key offerings; Exhibits138: Boehringer Ingelheim International GmbH - Overview; Exhibits139: Boehringer Ingelheim International GmbH - Business segments; Exhibits140: Boehringer Ingelheim International GmbH - Key news; Exhibits141: Boehringer Ingelheim International GmbH - Key offerings; Exhibits142: Boehringer Ingelheim International GmbH - Segment focus; Exhibits143: Bristol Myers Squibb Co. - Overview; Exhibits144: Bristol Myers Squibb Co. - Product / Service; Exhibits145: Bristol Myers Squibb Co. - Key news; Exhibits146: Bristol Myers Squibb Co. - Key offerings; Exhibits147: F. Hoffmann La Roche Ltd. - Overview; Exhibits148: F. Hoffmann La Roche Ltd. - Business segments; Exhibits149: F. Hoffmann La Roche Ltd. - Key news; Exhibits150: F. Hoffmann La Roche Ltd. - Key offerings; Exhibits151: F. Hoffmann La Roche Ltd. - Segment focus; Exhibits152: Gilead Sciences Inc. - Overview; Exhibits153: Gilead Sciences Inc. - Product / Service; Exhibits154: Gilead Sciences Inc. - Key news; Exhibits155: Gilead Sciences Inc. - Key offerings; Exhibits156: GlaxoSmithKline Plc - Overview; Exhibits157: GlaxoSmithKline Plc - Business segments; Exhibits158: GlaxoSmithKline Plc - Key news; Exhibits159: GlaxoSmithKline Plc - Key offerings; Exhibits160: GlaxoSmithKline Plc - Segment focus; Exhibits161: Immatics NV - Overview; Exhibits162: Immatics NV - Product / Service; Exhibits163: Immatics NV - Key offerings; Exhibits164: Johnson and Johnson - Overview; Exhibits165: Johnson and Johnson - Business segments; Exhibits166: Johnson and Johnson - Key news; Exhibits167: Johnson and Johnson - Key offerings; Exhibits168: Johnson and Johnson - Segment focus; Exhibits169: Novartis AG - Overview; Exhibits170: Novartis AG - Business segments; Exhibits171: Novartis AG - Key offerings; Exhibits172: Novartis AG - Segment focus; Exhibits173: Pfizer Inc. - Overview; Exhibits174: Pfizer Inc. - Product / Service; Exhibits175: Pfizer Inc. - Key news; Exhibits176: Pfizer Inc. - Key offerings; Exhibits177: Sanofi SA - Overview; Exhibits178: Sanofi SA - Business segments; Exhibits179: Sanofi SA - Key news; Exhibits180: Sanofi SA - Key offerings; Exhibits181: Sanofi SA - Segment focus; Exhibits182: Inclusions checklist; Exhibits183: Exclusions checklist; Exhibits184: Currency conversion rates for US$; Exhibits185: Research methodology; Exhibits186: Validation techniques employed for market sizing; Exhibits187: Information sources; Exhibits188: List of abbreviations